1217 GSK Surface
BioCentury & Getty Images


GSK adds to next-generation checkpoint pipeline with Surface deal

Dec 17, 2020 | 10:58 PM GMT

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. 

On Thursday, the partners announced that Surface Oncology Inc. (NASDAQ:SURF) granted GlaxoSmithKline plc (LSE:GSK;

Read the full 657 word article

How to gain access

Continue reading with a
two-week free trial.